TY - JOUR
T1 - Detection of oncogenes in chronic pancreatitis
AU - Paramythiotis, D.
AU - Kleeff, J.
AU - Schmidt, J.
AU - Büchler, J.
AU - Friess, Helmut
PY - 2003
Y1 - 2003
N2 - Background: The pathogenesis of chronic pancreatitis (CP) remains poorly understood. Recently, molecular biology has identified the genetic background for many patients with hereditary CP. In addition, a number of studies have focused on the detection of proto-oncogenes and tumour suppressor gene mutations in the pathogenesis of CP. So far, the use of these mutations (with the exception of mutations causing hereditary CP), as diagnostic and prognostic markers is still controversial. Discussion: It is well known that the risk of pancreatic cancer in patients with CP, especially the hereditary form, is high. At present, there is insufficient evidence to show a clear relationship between the development of pancreatic cancer and certain mutations. New biotechnological methods, such as DNA array expression analysis, expand our knowledge of the molecular pathogenesis of this disease and may help to develop specific diagnostic, prognostic and therapeutic tools. However, until long-term studies examine the safety and efficacy of certain genetic markers, long-term follow-up of patients with CP who harbour mutations is needed.
AB - Background: The pathogenesis of chronic pancreatitis (CP) remains poorly understood. Recently, molecular biology has identified the genetic background for many patients with hereditary CP. In addition, a number of studies have focused on the detection of proto-oncogenes and tumour suppressor gene mutations in the pathogenesis of CP. So far, the use of these mutations (with the exception of mutations causing hereditary CP), as diagnostic and prognostic markers is still controversial. Discussion: It is well known that the risk of pancreatic cancer in patients with CP, especially the hereditary form, is high. At present, there is insufficient evidence to show a clear relationship between the development of pancreatic cancer and certain mutations. New biotechnological methods, such as DNA array expression analysis, expand our knowledge of the molecular pathogenesis of this disease and may help to develop specific diagnostic, prognostic and therapeutic tools. However, until long-term studies examine the safety and efficacy of certain genetic markers, long-term follow-up of patients with CP who harbour mutations is needed.
KW - Cationic trypsinogen
KW - CFTR
KW - Chronic pancreatitis
KW - DNA array
KW - K-ras
KW - Mutation
KW - Oncogenes
KW - p53
KW - SPINK-1
UR - http://www.scopus.com/inward/record.url?scp=0347527377&partnerID=8YFLogxK
U2 - 10.1080/13651820310017804
DO - 10.1080/13651820310017804
M3 - Review article
AN - SCOPUS:0347527377
SN - 1365-182X
VL - 5
SP - 214
EP - 225
JO - HPB
JF - HPB
IS - 4
ER -